Sciencast Management’s ResMed RMD Stock Holding History

Sciencast Management’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,605	Closed	-$2.38M	–	348
2026 Q1	$2.38M	Sell	10,605 -4,348	-29%	-$1.08M	0.3%	134
2025 Q4	$3.6M	Buy	+14,953	New	+$3.82M	0.5%	88
2025 Q3	–	Sell	-9,745	Closed	-$2.51M	–	362
2025 Q2	$2.51M	Buy	+9,745	New	+$2.32M	0.52%	86
2020 Q4	–	Sell	-5,147	Closed	-$911K	–	593
2020 Q3	$911K	Buy	+5,147	New	+$950K	0.35%	96
2016 Q4	–	Sell	-3,099	Closed	-$203K	–	234
2016 Q3	$203K	Buy	+3,099	New	+$206K	0.6%	78

Other funds holding RMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Sciencast Management's RMD Position: Q2 2026 in Review

Sciencast Management sold out of ResMed (RMD) in Q2 2026, closing a stake of 10,605 shares — an estimated $2.38M sold.

Sciencast Management first reported a position in RMD in Q3 2016 and held it in 5 quarters. The position peaked at $3.6M in Q4 2025. 885 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

Sciencast Management reported no remaining ResMed position as of Q2 2026 after selling out during the quarter.
Sciencast Management sold 10,605 ResMed shares in Q2 2026, an estimated $2.38M.
Sciencast Management first reported a position in ResMed in Q3 2016 and held it in 5 quarters.
Sciencast Management's ResMed position peaked at $3.6M in Q4 2025.
885 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Sciencast Management's 13F filing for Q2 2026, filed 28 Jul 2026.